{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:01:27Z","timestamp":1794574887081,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95700-9","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T20:25:26Z","timestamp":1743020726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database"],"prefix":"10.1038","volume":"15","author":[{"given":"Yi","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youpeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"95700_CR1","doi-asserted-by":"publisher","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","volume":"66","author":"BMI Cabral","year":"2020","unstructured":"Cabral, B. M. I., Edding, S. N., Portocarrero, J. P. & Lerma, E. V. Rhabdomyolysis Dis. Mon. 66, 101015 (2020).","journal-title":"Dis. Mon."},{"key":"95700_CR2","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","volume":"142","author":"JL Levenson","year":"1985","unstructured":"Levenson, J. L. Neuroleptic malignant syndrome. Am. J. Psychiatry 142, 1137\u20131145 (1985).","journal-title":"Am. J. Psychiatry"},{"key":"95700_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/bmj.327.7407.115","volume":"327","author":"R Lane","year":"2003","unstructured":"Lane, R. & Phillips, M. Rhabdomyolysis BMJ 327, 115\u2013116 (2003).","journal-title":"BMJ"},{"key":"95700_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40560-016-0193-9","volume":"4","author":"T Yoshizawa","year":"2016","unstructured":"Yoshizawa, T. et al. Heat stroke with bimodal rhabdomyolysis: A case report and review of the literature. J. Intensive Care 4, 71 (2016).","journal-title":"J. Intensive Care"},{"key":"95700_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0378-4274(02)00010-3","volume":"128","author":"C Hodel","year":"2002","unstructured":"Hodel, C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128, 159\u2013168 (2002).","journal-title":"Toxicol. Lett."},{"key":"95700_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00000441-200308000-00005","volume":"326","author":"RC Allison","year":"2003","unstructured":"Allison, R. C. & Bedsole, D. L. The other medical causes of rhabdomyolysis. Am. J. Med. Sci. 326, 79\u201388 (2003).","journal-title":"Am. J. Med. Sci."},{"key":"95700_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1378\/chest.12-2016","volume":"144","author":"JL Zimmerman","year":"2013","unstructured":"Zimmerman, J. L. & Shen, M. C. Rhabdomyolysis. Chest 144, 1058\u20131065 (2013).","journal-title":"Chest"},{"key":"95700_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.medcli.2021.09.025","volume":"158","author":"R Baeza-Trinidad","year":"2022","unstructured":"Baeza-Trinidad, R. & Rhabdomyolysis: A syndrome to be considered. Med. Clin. 158, 277\u2013283 (2022).","journal-title":"Med. Clin."},{"key":"95700_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2215-0366(24)00163-9","volume":"11","author":"PD McGorry","year":"2024","unstructured":"McGorry, P. D. et al. The lancet psychiatry commission on youth mental health. Lancet Psychiatry 11, 731\u2013774 (2024).","journal-title":"Lancet Psychiatry"},{"key":"95700_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1176\/appi.ajp.20240738","volume":"181","author":"S Leucht","year":"2024","unstructured":"Leucht, S., Priller, J. & Davis, J. M. Antipsychotic drugs: A concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application. Am. J. Psychiatry 181, 865\u2013878 (2024).","journal-title":"Am. J. Psychiatry"},{"key":"95700_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht, S. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 373, 31\u201341 (2009).","journal-title":"Lancet"},{"key":"95700_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","volume":"121","author":"H Verdoux","year":"2010","unstructured":"Verdoux, H., Tournier, M. & B\u00e9gaud, B. Antipsychotic prescribing trends: A review of pharmaco-epidemiological studies. Acta Psychiatr. Scand. 121, 4\u201310 (2010).","journal-title":"Acta Psychiatr. Scand."},{"key":"95700_CR13","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1176\/appi.ajp.159.8.1435","volume":"159","author":"SH Yang","year":"2002","unstructured":"Yang, S. H. & McNeely, M. J. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am. J. Psychiatry 159, 1435 (2002).","journal-title":"Am. J. Psychiatry"},{"key":"95700_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JCP.0000000000001292","volume":"40","author":"T Li","year":"2020","unstructured":"Li, T. et al. Quetiapine-associated rhabdomyolysis: A case report and literature review. J. Clin. Psychopharmacol. 40, 619\u2013624 (2020).","journal-title":"J. Clin. Psychopharmacol."},{"key":"95700_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1136\/postgradmedj-2021-141118","volume":"98","author":"A Ioannou","year":"2022","unstructured":"Ioannou, A. & Perera, D. Delayed olanzapine induced myocarditis and rhabdomyolysis. Postgrad. Med. J. 98, 824 (2022).","journal-title":"Postgrad. Med. J."},{"key":"95700_CR16","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng, Z., Wang, S., Wu, C. & Wang, C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front. Pharmacol. 14, 1124628 (2023).","journal-title":"Front. Pharmacol."},{"key":"95700_CR17","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm, R. et al. OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One 11, e0157753 (2016).","journal-title":"PLoS One"},{"key":"95700_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"95700_CR19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","volume":"29","author":"Y Shu","year":"2023","unstructured":"Shu, Y., Ding, Y., Liu, L. & Zhang, Q. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system. CNS Neurosci. Ther. 29, 2705\u20132716 (2023).","journal-title":"CNS Neurosci. Ther."},{"key":"95700_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita, S., Hosomi, K., Yokoyama, S. & Takada, M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J. Clin. Pharm. Ther. 45, 65\u201371 (2020).","journal-title":"J. Clin. Pharm. Ther."},{"key":"95700_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2165\/00007256-200232020-00003","volume":"32","author":"B Kendall","year":"2002","unstructured":"Kendall, B. & Eston, R. Exercise-induced muscle damage and the potential protective role of estrogen. Sports Med. 32, 103\u2013123 (2002).","journal-title":"Sports Med."},{"key":"95700_CR22","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s40279-022-01733-9","volume":"52","author":"A Pellegrino","year":"2022","unstructured":"Pellegrino, A., Tiidus, P. M. & Vandenboom, R. Mechanisms of estrogen influence on skeletal muscle: Mass, regeneration, and mitochondrial function. Sports Med. 52, 2853\u20132869 (2022).","journal-title":"Sports Med."},{"key":"95700_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.tpj.6500378","volume":"6","author":"WM Cai","year":"2006","unstructured":"Cai, W. M. et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: Implications for clinical practice and genetic testing. Pharmacogenomics J. 6, 343\u2013350 (2006).","journal-title":"Pharmacogenomics J."},{"key":"95700_CR24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/sj.mp.4002136","volume":"14","author":"S Leucht","year":"2009","unstructured":"Leucht, S., Arbter, D., Engel, R. R., Kissling, W. & Davis, J. M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 14, 429\u2013447 (2009).","journal-title":"Mol. Psychiatry"},{"key":"95700_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht, S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet 382, 951\u2013962 (2013).","journal-title":"Lancet"},{"key":"95700_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","volume":"157","author":"L Hartling","year":"2012","unstructured":"Hartling, L. et al. Antipsychotics in adults with schizophrenia: Comparative effectiveness of first-generation versus second-generation medications\u2014a systematic review and meta-analysis. Ann. Intern. Med. 157, 498\u2013511 (2012).","journal-title":"Ann. Intern. Med."},{"key":"95700_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","volume":"37","author":"FP Bymaster","year":"1999","unstructured":"Bymaster, F. P. et al. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, Histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr. Res. 37, 107\u2013122 (1999).","journal-title":"Schizophr. Res."},{"issue":"Suppl 13","key":"95700_CR28","first-page":"5","volume":"63","author":"CB Nemeroff","year":"2002","unstructured":"Nemeroff, C. B., Kinkead, B. & Goldstein, J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions, and dosing. J. Clin. Psychiatry 63(Suppl 13), 5\u201311 (2002).","journal-title":"J. Clin. Psychiatry"},{"key":"95700_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238\u2013246 (1989).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"95700_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1006\/bbrc.1999.0471","volume":"257","author":"E Hajduch","year":"1999","unstructured":"Hajduch, E. et al. Biochemical localisation of the 5-HT2A (serotonin) receptor in rat skeletal muscle. Biochem. Biophys. Res. Commun. 257, 369\u2013372 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"95700_CR31","doi-asserted-by":"crossref","unstructured":"Sikand, H., Jaojoco, J., Linares, L. & Phillips, P. S. Atypical antipsychotic drugs, dementia, and risk of death. JAMA 295, 495 (2006) (author reply 496\u2013497).","DOI":"10.1001\/jama.295.5.495-a"},{"key":"95700_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2174\/157488609789007010","volume":"4","author":"LA Linares","year":"2009","unstructured":"Linares, L. A., Golomb, B. A., Jaojoco, J. A., Sikand, H. & Phillips, P. S. The modern spectrum of rhabdomyolysis: Drug toxicity revealed by creatine kinase screening. Curr. Drug Saf. 4, 181\u2013187 (2009).","journal-title":"Curr. Drug Saf."},{"key":"95700_CR33","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.2174\/1381612821666150619092903","volume":"21","author":"L Carton","year":"2015","unstructured":"Carton, L. et al. Off-Label prescribing of antipsychotics in adults, children and elderly individuals: A systematic review of recent prescription trends. Curr. Pharm. Des. 21, 3280\u20133297 (2015).","journal-title":"Curr. Pharm. Des."},{"key":"95700_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1192\/bjb.2020.80","volume":"46","author":"L Carey","year":"2022","unstructured":"Carey, L. & Barlow, S. Review of antipsychotic prescribing at HMP\/YOI low Newton. BJPsych Bull. 46, 26\u201332 (2022).","journal-title":"BJPsych Bull."},{"key":"95700_CR35","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.2147\/PPA.S495254","volume":"18","author":"C De Las Cuevas","year":"2024","unstructured":"De Las Cuevas, C., Sanz, E. J. & de Leon, J. Pharmacovigilance in action: Utilizing vigibase data to improve clozapine safety. Patient Prefer. Adherence 18, 2261\u20132280 (2024).","journal-title":"Patient Prefer. Adherence"},{"key":"95700_CR36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1089\/cap.2011.0134","volume":"22","author":"K Star","year":"2012","unstructured":"Star, K. et al. Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: A case series analysis. J. Child. Adolesc. Psychopharmacol. 22, 440\u2013451 (2012).","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"95700_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4088\/JCP.v64n0420f","volume":"64","author":"E Mart\u00ed-Bonmat\u00ed","year":"2003","unstructured":"Mart\u00ed-Bonmat\u00ed, E., San Valero-Carcel\u00e9n, E., Ortega-Garc\u00eda, M. P. & Rubini-Puig, R. Olanzapine elevation of serum creatine kinase. J. Clin. Psychiatry 64, 483\u2013484 (2003).","journal-title":"J. Clin. Psychiatry"},{"key":"95700_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1177\/0960327106073832","volume":"25","author":"WS Waring","year":"2006","unstructured":"Waring, W. S., Wrate, J. & Bateman, D. N. Olanzapine overdose is associated with acute muscle toxicity. Hum. Exp. Toxicol. 25, 735\u2013740 (2006).","journal-title":"Hum. Exp. Toxicol."},{"key":"95700_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s002130000539","volume":"152","author":"S Devarajan","year":"2000","unstructured":"Devarajan, S. & Dursun, S. M. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology 152, 122 (2000).","journal-title":"Psychopharmacol. (Berl)"},{"key":"95700_CR40","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1212\/WNL.47.6.1518","volume":"47","author":"SN Scelsa","year":"1996","unstructured":"Scelsa, S. N. et al. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 47, 1518\u20131523 (1996).","journal-title":"Neurology"},{"key":"95700_CR41","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1001\/jamapsychiatry.2016.1520","volume":"73","author":"KF Huybrechts","year":"2016","unstructured":"Huybrechts, K. F. et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 73, 938\u2013946 (2016).","journal-title":"JAMA Psychiatry"},{"key":"95700_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jamapsychiatry.2022.4109","volume":"80","author":"KF Huybrechts","year":"2023","unstructured":"Huybrechts, K. F. et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in nordic countries and the US. JAMA Psychiatry 80, 156\u2013166 (2023).","journal-title":"JAMA Psychiatry"},{"key":"95700_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00737-022-01221-z","volume":"25","author":"R Gyawali","year":"2022","unstructured":"Gyawali, R. et al. Novel report on congenital Talipes Equinovarus (CTEV) following olanzapine exposure during pregnancy: Case report and short review. Arch. Womens Ment. Health 25, 671\u2013674 (2022).","journal-title":"Arch. Womens Ment Health"},{"key":"95700_CR44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bdi.12325","volume":"17","author":"BJ Wlodarczyk","year":"2015","unstructured":"Wlodarczyk, B. J., Ogle, K., Lin, L. Y., Bialer, M. & Finnell, R. H. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 17, 615\u2013625 (2015).","journal-title":"Bipolar Disord."},{"key":"95700_CR45","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra0801327","volume":"361","author":"X Bosch","year":"2009","unstructured":"Bosch, X., Poch, E. & Grau, J. M. Rhabdomyolysis and acute kidney injury. N Engl. J. Med. 361, 62\u201372 (2009).","journal-title":"N Engl. J. Med."},{"key":"95700_CR46","doi-asserted-by":"publisher","first-page":"303","DOI":"10.32098\/mltj.04.2013.11","volume":"3","author":"E Keltz","year":"2013","unstructured":"Keltz, E., Khan, F. Y. & Mann, G. Rhabdomyolysis. The role of diagnostic and prognostic factors. Muscles Ligaments Tendons J. 3, 303\u2013312 (2013).","journal-title":"Muscles Ligaments Tendons J."},{"issue":"Suppl 1","key":"95700_CR47","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1055\/s-2006-931485","volume":"39","author":"G Gr\u00fcnder","year":"2006","unstructured":"Gr\u00fcnder, G., Kungel, M., Ebrecht, M., G\u00f6r\u00f6cs, T. & Modell, S. Aripiprazole: Pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 39(Suppl 1), S21\u201325 (2006).","journal-title":"Pharmacopsychiatry"},{"key":"95700_CR48","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","volume":"16","author":"JK McGavin","year":"2002","unstructured":"McGavin, J. K. & Goa, K. L. Aripiprazole. CNS Drugs 16, 779\u2013786 (2002). (discussion 787\u2013788).","journal-title":"CNS Drugs"},{"key":"95700_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1176\/appi.ajp.2008.07101574","volume":"165","author":"G Gr\u00fcnder","year":"2008","unstructured":"Gr\u00fcnder, G. et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am. J. Psychiatry 165, 988\u2013995 (2008).","journal-title":"Am. J. Psychiatry"},{"key":"95700_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/npp.2008.166","volume":"34","author":"DF Wong","year":"2009","unstructured":"Wong, D. F., Tauscher, J. & Gr\u00fcnder, G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 34, 187\u2013203 (2009).","journal-title":"Neuropsychopharmacology"},{"key":"95700_CR51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.schres.2021.01.006","volume":"228","author":"J Oh","year":"2021","unstructured":"Oh, J., Nam, H., Park, S., Chae, J. H. & Kim, T. S. Decreased cardiovascular death in schizophrenia patients treated with antipsychotics: A Korean national cohort study. Schizophr. Res. 228, 417\u2013424 (2021).","journal-title":"Schizophr. Res."},{"key":"95700_CR52","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1517\/13543784.2014.971152","volume":"23","author":"MF Moro","year":"2014","unstructured":"Moro, M. F. & Carta, M. G. Evaluating aripiprazole as a potential bipolar disorder therapy for adults. Expert Opin. Investig. Drugs 23, 1713\u20131730 (2014).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"95700_CR53","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","volume":"30","author":"L Citrome","year":"2014","unstructured":"Citrome, L., Kalsekar, I., Baker, R. A. & Hebden, T. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr. Med. Res. Opin. 30, 1629\u20131641 (2014).","journal-title":"Curr. Med. Res. Opin."},{"key":"95700_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/11208400-000000000-00000","volume":"26","author":"JD Croxtall","year":"2012","unstructured":"Croxtall, J. D. Aripiprazole: A review of its use in the management of schizophrenia in adults. CNS Drugs 26, 155\u2013183 (2012).","journal-title":"CNS Drugs"},{"key":"95700_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s002130000465","volume":"150","author":"HY Meltzer","year":"2000","unstructured":"Meltzer, H. Y. Massive serum creatine kinase increases with atypical antipsychotic drugs: What is the mechanism and the message? Psychopharmacology 150, 349\u2013350 (2000).","journal-title":"Psychopharmacology"},{"key":"95700_CR56","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/jcpt.12205","volume":"39","author":"YC Hsu","year":"2014","unstructured":"Hsu, Y. C. & Yeh, Y. W. Multidrug overdose-induced myoclonus complicated by rhabdomyolysis: Possible role and mechanism of muscle toxicity of risperidone. J. Clin. Pharm. Ther. 39, 698\u2013700 (2014).","journal-title":"J. Clin. Pharm. Ther."},{"key":"95700_CR57","doi-asserted-by":"publisher","first-page":"279","DOI":"10.11622\/smedj.2016094","volume":"57","author":"YF Lee","year":"2016","unstructured":"Lee, Y. F. et al. Delayed-onset rhabdomyolysis related to olanzapine: A case report. Singap. Med. J. 57, 279 (2016).","journal-title":"Singap. Med. J."},{"key":"95700_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/PL00005334","volume":"359","author":"J Fang","year":"1999","unstructured":"Fang, J., Bourin, M. & Baker, G. B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch. Pharmacol. 359, 147\u2013151 (1999).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"95700_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12888-020-03034-9","volume":"21","author":"J Lu","year":"2021","unstructured":"Lu, J. et al. Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry 21, 70 (2021).","journal-title":"BMC Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95700-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95700-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T09:30:07Z","timestamp":1743327007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95700-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95700"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95700-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"10499"}}